Purdue’s groundbreaking treatment for prostate cancer | AI improves care for diabetes

Purdue’s new therapy for prostate cancer

WEST LAFAYETTE, IN–Groundbreaking research from Purdue professor Philip Low, at the Purdue University College of Science’s Department of Chemistry, laid the foundation for a new precision, targeted therapy for advanced prostate cancer. The treatment has been granted approval by the U.S. Food and Drug Administration.

Screening voices for evidence of coronary artery disease

ROCHESTER, MN–Researchers at the Mayo Clinic have developed an AI tool that can screen a patient’s voice recording for evidence of coronary artery disease (CAD). The smartphone app for AI voice analysis is able to accurately predict which patients have clogged arteries, which can cause heart attacks.

President Biden taps Case Western engineer for expertise

CLEVELAND, OH–When President Biden spoke to reporters about the promise of a new federal biomedical research agency—called the Advanced Research Projects Agency for Health—he tapped Case Western Reserve University biomedical engineer Dustin Tyler and a few of the nation’s other leading scientists and healthcare experts to join him. After the event, the President then met privately with the experts, as well as a patient using an innovative prosthetic limb that Tyler developed.

AI for improving diabetes care

INDIANAPOLIS, IN—The Regenstrief Institute, along with Hitachi, Ltd. and the University of Utah Health, will work to develop an AI method to improve care for patients with type 2 diabetes mellitus who need complex treatment. The Regenstrief Institute, Inc., a not-for-profit health care research organization, is closely affiliated with the Indiana University School of Medicine, Roudebush VA Medical Center, IU Health, and Eskenazi Health, among other research partners.

Blood test to assess organ damage from COVID

KANSAS CITY, MO—Clinical specialty lab Eurofins Viracor will start offering a cutting-edge blood test that can assess organ damage from COVID-19. The company has entered into an exclusive agreement with Cornell University to begin using its novel, noninvasive blood test that uses circulating cell-free DNA to gauge the damage that COVID-19 inflicts on cells, tissues and organs.